Meeting
2020 Gastrointestinal Cancers Symposium
Comparative efficacy of second-line treatments for advanced hepatocellular carcinoma: A network meta-analysis.
Authors
Neehar Parikh
University of Michigan, Ann Arbor, MI
Neehar Parikh , Alexander Marshall , Keith D. Huff , Rachel Savidge , Keith A. Betts , Jinlin Song , Jing Zhao , Muhan Yuan , Richard D. Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 545)
Abstract #
545
Poster Bd #
D6
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Immunotherapy versus biologics as second-line therapy in advanced hepatocellular carcinoma (HCC).
First Author: Mohammed Al-Jumayli
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib (P+L) versus alternative therapies in first-line (1L) advanced renal cell carcinoma (aRCC) by IMDC risk status: A network meta-analysis (NMA).
First Author: Pratik Rane
Poster
2023 ASCO Annual Meeting
Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma.
First Author: Geoffrey Thomas Gibney
Poster
2023 ASCO Annual Meeting
Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.
First Author: Thierry Landre